Demarchis L, Chiloiro S, Giampietro A, De Marinis L, Bianchi A, Fleseriu M
Rev Endocr Metab Disord. 2025; .
PMID: 40088375
DOI: 10.1007/s11154-025-09957-6.
Zhang X, Xue H, Lv Y, Zhou Y, Sha K, Liu T
Discov Oncol. 2025; 16(1):320.
PMID: 40088344
DOI: 10.1007/s12672-025-02070-9.
Ortega-Batista A, Jaen-Alvarado Y, Moreno-Labrador D, Gomez N, Garcia G, Guerrero E
Int J Mol Sci. 2025; 26(5).
PMID: 40076700
PMC: 11901077.
DOI: 10.3390/ijms26052074.
Almawash S
Cancers (Basel). 2025; 17(5).
PMID: 40075727
PMC: 11899125.
DOI: 10.3390/cancers17050880.
Jaume J
Cancers (Basel). 2025; 17(5).
PMID: 40075642
PMC: 11899416.
DOI: 10.3390/cancers17050794.
Risk Factors for Intrahepatic Distant Recurrence After Radiofrequency Ablation for Hepatocellular Carcinoma.
Tsuji Y, Namisaki T, Takaya H, Nishimura N, Noguchi R, Asada S
Dig Dis Sci. 2025; .
PMID: 40072765
DOI: 10.1007/s10620-025-08884-5.
Antibody-positive paraneoplastic neurological syndromes associated with immune checkpoint inhibitors: a systematic review.
Zhang L, Fan S, Wang J, Ren H, Guan H
J Neurol. 2025; 272(3):249.
PMID: 40042691
DOI: 10.1007/s00415-025-12992-7.
High baseline levels of PD-L1 reduce the heterogeneity of immune checkpoint signature and sensitize anti-PD1 therapy in lung and colorectal cancers.
Fan P, Qi Z, Liu Z, Wang S, Wang Y, Kuai J
Cell Death Dis. 2025; 16(1):152.
PMID: 40038236
PMC: 11880386.
DOI: 10.1038/s41419-025-07471-w.
Coordinated macrophage and T cell interactions mediate response to checkpoint blockade in colorectal cancer.
Mestrallet G, Brown M, Vaninov N, Cho N, Velazquez L, Ananthanarayanan A
bioRxiv. 2025; .
PMID: 40027748
PMC: 11870396.
DOI: 10.1101/2025.02.12.637954.
Prognostic Value of Circulating Lymphocyte Subsets in Cervical Cancer Following Postoperative Radiotherapy.
Wang S, Zhao M, Gao Z, Yang X, Lu Y, Fu J
Int J Med Sci. 2025; 22(5):1029-1038.
PMID: 40027185
PMC: 11866531.
DOI: 10.7150/ijms.107392.
Liver Metastasis in Cancer: Molecular Mechanisms and Management.
Xu W, Xu J, Liu J, Wang N, Zhou L, Guo J
MedComm (2020). 2025; 6(3):e70119.
PMID: 40027151
PMC: 11868442.
DOI: 10.1002/mco2.70119.
Cell-type-specific requirement for TYK2 in murine immune cells under steady state and challenged conditions.
Karjalainen A, Witalisz-Siepracka A, Prchal-Murphy M, Martin D, Sternberg F, Krunic M
Cell Mol Life Sci. 2025; 82(1):98.
PMID: 40025196
PMC: 11872851.
DOI: 10.1007/s00018-025-05625-9.
How modulation of the tumor microenvironment drives cancer immune escape dynamics.
Shrestha P, Ghoreyshi Z, George J
Sci Rep. 2025; 15(1):7308.
PMID: 40025156
PMC: 11873109.
DOI: 10.1038/s41598-025-91396-z.
Cancer Vaccines and Beyond: The Transformative Role of Nanotechnology in Immunotherapy.
Delgado-Almenta V, Blaya-Canovas J, Calahorra J, Lopez-Tejada A, Grinan-Lison C, Granados-Principal S
Pharmaceutics. 2025; 17(2).
PMID: 40006583
PMC: 11859086.
DOI: 10.3390/pharmaceutics17020216.
Intra-Tumoral Lymphocytic Infiltration Is Associated with Favorable Prognosis in Suboptimal Surgery in High-Grade Serous Ovarian Carcinoma.
Harada H, Hachisuga T, Harada Y, Shibahara M, Murakami M, Nuratdinova F
Diagnostics (Basel). 2025; 15(4).
PMID: 40002574
PMC: 11854212.
DOI: 10.3390/diagnostics15040422.
Non-small cell lung cancer and the tumor microenvironment: making headway from targeted therapies to advanced immunotherapy.
De Lucia A, Mazzotti L, Gaimari A, Zurlo M, Maltoni R, Cerchione C
Front Immunol. 2025; 16:1515748.
PMID: 39995659
PMC: 11847692.
DOI: 10.3389/fimmu.2025.1515748.
Immunotherapy rechallenge after significant toxicity - can it be done successfully?.
Tan A, McSweeney T, Sikotra N, Adler B, van Hagen T, Summers Q
Immunotherapy. 2025; 17(2):103-111.
PMID: 39995195
PMC: 11906110.
DOI: 10.1080/1750743X.2025.2452838.
Tumor microenvironment as a novel therapeutic target for lymphoid leukemias.
Mousavi S, Nouri S, Sadeghipour A, Atashi A
Ann Hematol. 2025; .
PMID: 39994019
DOI: 10.1007/s00277-025-06237-w.
Overexpression of MCM3 as a prognostic biomarker correlated with cell proliferation, cell cycle and immune regulation in hepatocellular carcinoma.
Ju L, Wang H, Luo Y, Wang Y, Chen L, Han X
J Cancer. 2025; 16(5):1538-1554.
PMID: 39991578
PMC: 11843239.
DOI: 10.7150/jca.104325.
Toll-like receptor 3: a double-edged sword.
Hsieh M, Nishizaki D, Adashek J, Kato S, Kurzrock R
Biomark Res. 2025; 13(1):32.
PMID: 39988665
PMC: 11849352.
DOI: 10.1186/s40364-025-00739-5.